Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK

Roger Williams (Lead / Corresponding author), Graeme Alexander, Iain Armstrong, Alastair Baker, Neeraj Bhala, Ginny Camps-Walsh, Matthew E. Cramp, Simon de Lusignan, Natalie Day, Anil Dhawan, John Dillon, Colin Drummond, Jessica Dyson, Graham Foster, Ian Gilmore, Mark Hudson, Deirdre Kelly, Andrew Langford, Neil McDougall, Petra MeierKieran Moriarty, Philip Newsome, John O'Grady, Rachel Pryke, Liz Rolfe, Peter Rice, Harry Rutter, Nick Sheron, Alison Taylor, Jeremy Thompson, Douglas Thorburn, Julia Verne, John Wass, Andrew Yeoman

Research output: Contribution to journalReview article

57 Citations (Scopus)
484 Downloads (Pure)

Abstract

This report contains new and follow-up metric data relating to the eight main recommendations of the Lancet Standing Commission on Liver Disease in the UK, which aim to reduce the unacceptable harmful consequences of excess alcohol consumption, obesity, and viral hepatitis. For alcohol, we provide data on alcohol dependence, damage to families, and the documented increase in alcohol consumption since removal of the above-inflation alcohol duty escalator. Alcoholic liver disease will shortly overtake ischaemic heart disease with regard to years of working life lost. The rising prevalence of overweight and obesity, affecting more than 60% of adults in the UK, is leading to an increasing liver disease burden. Favourable responses by industry to the UK Government's soft drinks industry levy have been seen, but the government cannot continue to ignore the number of adults being affected by diabetes, hypertension, and liver disease. New direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection have reduced mortality and the number of patients requiring liver transplantation, but more screening campaigns are needed for identification of infected people in high-risk migrant communities, prisons, and addiction centres. Provision of care continues to be worst in regions with the greatest socioeconomic deprivation, and deficiencies exist in training programmes in hepatology for specialist registrars. Firm guidance is needed for primary care on the use of liver blood tests in detection of early disease and the need for specialist referral. This report also brings together all the evidence on costs to the National Health Service and wider society, in addition to the loss of tax revenue, with alcohol misuse in England and Wales costing £21 billion a year (possibly up to £52 billion) and obesity costing £27 billion a year (treasury estimates are as high as £46 billion). Voluntary restraints by the food and drinks industry have had little effect on disease burden, and concerted regulatory and fiscal action by the UK Government is essential if the scale of the medical problem, with an estimated 63 000 preventable deaths over the next 5 years, is to be addressed.

Original languageEnglish
Pages (from-to)1097-1107
Number of pages11
JournalLancet
Volume391
Issue number10125
Early online date29 Nov 2017
DOIs
Publication statusPublished - 17 Mar 2018

Keywords

  • Journal article
  • Review
  • Health Care Costs
  • Humans
  • Cost of Illness
  • Hepatitis, Viral, Human/complications
  • Obesity/complications
  • Liver Diseases, Alcoholic/economics
  • United Kingdom/epidemiology
  • Alcohol Drinking/adverse effects

Fingerprint Dive into the research topics of 'Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the <i>Lancet</i> Standing Commission on Liver Disease in the UK'. Together they form a unique fingerprint.

  • Cite this

    Williams, R., Alexander, G., Armstrong, I., Baker, A., Bhala, N., Camps-Walsh, G., Cramp, M. E., de Lusignan, S., Day, N., Dhawan, A., Dillon, J., Drummond, C., Dyson, J., Foster, G., Gilmore, I., Hudson, M., Kelly, D., Langford, A., McDougall, N., ... Yeoman, A. (2018). Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK. Lancet, 391(10125), 1097-1107. https://doi.org/10.1016/S0140-6736(17)32866-0